What the evidence shows
- Bacopa trials in the review used no other medication.
- The pediatric citicoline trial found no significant difference from a dummy pill.
- The citicoline trial reported no adverse effects in its study.
- The piracetam study tested piracetam and atomoxetine as single treatments.
What the studies examined
The cited papers studied different supplements and different groups. Their results do not come from one shared trial.
The Bacopa review included trials without any other medication. A citicoline trial studied children diagnosed with ADHD. A separate study compared piracetam and atomoxetine as single treatments in children with ADHD.
Bacopa findings came from trials without other medication
A review included nine randomized trials with 518 people. The trials tested standardized Bacopa extracts for at least 12 weeks, without other medication. The review rated trial bias as low and reported information quality as high.
In a meta-analysis of 437 participants, Trail B test time shortened by 17.9 milliseconds. Choice reaction time decreased by 10.6 milliseconds. Both results had p-values below 0.001. The authors said Bacopa may improve cognition, especially attention speed. They said a large, well-designed comparison with an existing medication would provide definitive evidence for healthy people or people with dementia.
The citicoline trial in children with ADHD
A randomized, crossover, double-blind trial compared citicoline with a dummy pill in children aged 7 to 12 years with ADHD. It found no statistically significant difference on the measures assessed.
The study reported no adverse effects. Its authors described citicoline as appearing safe for children and said further studies were needed to assess its potential in ADHD.
Piracetam was compared with atomoxetine as a single treatment
An open, controlled study included 42 children with ADHD, aged 6 to 13 years. One group received atomoxetine alone, another received piracetam alone, and a third received no drug treatment.
The study reported high effectiveness for both drugs. Atomoxetine's effect appeared after two weeks and was more pronounced across all syndrome components than piracetam's effect. This study did not test piracetam alongside atomoxetine.
What these findings establish
These papers report findings from separate designs and populations. The Bacopa review expressly included trials without other medication. The piracetam study tested each drug alone. The citicoline trial compared citicoline with a dummy pill in children with ADHD.
The reported results describe those study settings. They do not establish what happens when people combine these supplements with prescribed stimulant medication.
Sources
- Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. Journal of ethnopharmacology, 2014
- Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study. Clinical neuropharmacology, 2024
- [Atomoxetine and piracetam in the treatment of attention deficit hyperactivity disorder in children]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008
About this article
NootroWorld publishes research summaries, not medical advice. This article describes what studies have and have not established; it does not tell you what to take. Supplements can interact with medication, pregnancy and existing health conditions, and study populations often differ from your own situation. Discuss any personal decision with a qualified healthcare professional.
